会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Synthesis of 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5[2-(phenylsulfonyl)ethyl]-1H-indole
    • 3 - {[(2R)-1-甲基吡咯烷-2-基]甲基} -5 [2-(苯基磺酰基)乙基] -1H-吲哚
    • US08426612B2
    • 2013-04-23
    • US12995390
    • 2009-11-09
    • Siro SerafiniAndrea CastellinClaudio Dal Santo
    • Siro SerafiniAndrea CastellinClaudio Dal Santo
    • C07D209/04
    • C07D403/06
    • The present invention refers to the synthesis of 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole, a drug known by the name Eletriptan, or of its salts. In particular, the present invention regards a process for the synthesis of Eletriptan or of its salt, comprising the following steps: a) Salifying the intermediate of Formula (6), using a dicarboxylic acid to obtain a derived salt; b) Optionally, purifying said raw salt obtained according to step a) by solvent crystallization to obtain a purified salt of the intermediate of Formula (6); c) Converting said salt of the intermediate of formula (6) according to step a) or said purified salt according to step b) into an intermediate of formula (10); d) Converting the intermediate of Formula (10) into Eletriptan or its salt.
    • 本发明涉及合成名为Eletriptan的3 - {[(2R)-1-甲基吡咯烷-2-基]甲基} -5- [2-(苯基磺酰基)乙基] -1H-吲哚, 或其盐。 特别地,本发明涉及一种合成埃曲普坦或其盐的方法,包括以下步骤:a)使用二羧酸使式(6)的中间体盐化得到衍生的盐; b)任选地,通过溶剂结晶纯化根据步骤a)获得的所述生盐,得到式(6)中间体的纯化盐; c)根据步骤a)将所述式(6)的中间体的盐或根据步骤b)的所述纯化盐转化成式(10)的中间体; d)将式(10)的中间体转化成Eletriptan或其盐。
    • 7. 发明申请
    • SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLO[3,4-b]PYRIDINE
    • (4aS,7aS)-OCTAHYDRO-1H-吡咯并[3,4-b]吡啶的合成
    • US20110137036A1
    • 2011-06-09
    • US13056458
    • 2010-03-04
    • Riccardo MotterleGiancarlo ArvottiElisabetta BergantinoAndrea CastellinStefano FogalMarco Galvagni
    • Riccardo MotterleGiancarlo ArvottiElisabetta BergantinoAndrea CastellinStefano FogalMarco Galvagni
    • C07D471/04C07D211/62C12P17/18C12P17/12
    • C07D211/16C07D471/04
    • The present invention relates to the stereoselective synthesis of (4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridine, as well as the conversion thereof, to give Moxifloxacin. Particularly, the present invention relates to a method for the synthesis of (4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridine of formula (I) comprising: (a) the optical resolution by enzymatic hydrolysis of the intermediate dialkyl-1-alkylcarbonylpiperidine-2,3-dicarboxylate racemate of formula (II) to give, following isolation, the intermediate dialkyl-(2S,3R)-1-alkylcarbonyl-piperidine-2,3-dicarboxylate of formula (III) in which AIk is a straight or branched C1-C5 alkyl group; (b) the conversion of the intermediate (III) to (4aR,7aS)-1-alkylcarbonylhexahydrofuro[3,4-b]pyridine-5,7-dione of formula (IV) in which AIk has the meanings set forth above; (c) the conversion of the intermediate (IV) to (4aS,7as)-octahydro-1H-pyrrolo[3,4-b]pyridine of formula (I) with an optical purity above 99%.
    • 本发明涉及(4aS,7aS) - 八氢-1H-吡咯并[3,4-b]吡啶的立体选择性合成及其转化,得到莫西沙星。 特别地,本发明涉及合成式(I)的(4aS,7aS) - 八氢-1H-吡咯并[3,4-b]吡啶的方法,包括:(a)通过酶水解的光学拆分 中间体式(II)的二烷基-1-烷基羰基哌啶-2,3-二甲酸酯外消旋物,分离后得到中间体式(III)的二烷基 - (2S,3R)-1-烷基羰基 - 哌啶-2,3-二甲酸酯 其中Alk是直链或支链C 1 -C 5烷基; (b)将式(Ⅳ)中间体(III)转化为式(Ⅳ)的(4aR,7aS)-1-烷基羰基六氢呋喃并[3,4-b]吡啶-5,7-二酮,其中Alk具有上述含义; (c)以99%以上的光学纯度转化为式(I)的中间体(IV)至(4aS,7as) - 八氢-1H-吡咯并[3,4-b]吡啶。